REPL

Conviction 92HealthcareScan · Mon, Jul 20, 2026

REPL$10.52+2.79%

ResistanceSupportVol 14Insider sell

Vol MA14 3.36M

Apr 20May 6May 26Jun 11Jul 1Jul 20

Replimune Group, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.replimune.com ↗

Price10.52

Change+2.79%

Gap+0.24%

Rel volume3.04×

Avg volume3.6M

Avg $ vol39.21M

SMA 2010.88

SMA 508.51

SMA 2007.64

Price vs 50+23.62%

Price vs 200+37.60%

MA stackbullish

50/200 crossgolden · 7d

Supertrendup · 8.87

RSI (14)56

MACD hist-0.29

MACD cross—

Stoch %K / %D45 / 33

ADX (14)28

+DI / −DI26 / 21

RSI divergence—

MACD divergence—

ATR %+7.94%

ADR %7.99%

52w high12.33

52w low1.70

From 52w high-14.69%

Above 52w low+518.53%

New 52w highNo

SqueezeOff

Bollinger width24.00%

%B0.36

Donchian pos44.71%

Donchian high12.50

Donchian low8.91

AVWAP (52w high)6.10

vs AVWAP high+72.34%

AVWAP (52w low)5.45

vs AVWAP low+92.93%

OBV trendFlat

Chaikin MF (20)0.08

Today vs 20d3.04×

Avg vol (14d)3.36M

Avg vol (20d)3.6M

Avg $ vol (20d)39.21M

Market cap882.68M

RS 3m (vs SPY)+361.19%

RS 6m (vs SPY)+25.02%

RS line new highNo

Trend template6/8

Technical rank90.1

1 week+5.84%

1 month+5.15%

3 months+384.56%

6 months+44.04%

1 year-15.88%

YTD+18.15%

P/E-2.81

P/B5.31

P/S—

P/FCF-3.12

EPS-3.38

Div yield—

ROE-188.94%

ROA-94.45%

Debt/Eq0.50

Current4.79

EV/EBITDA-2.39

Gross margin—

Net margin—

Rev growth—

EPS growth-26.95%

Price target14.00

Target upside33.14%

Analyst ratingBuy

Institutional101.11%

Ent. value756.97M

Revenue0

Net income-70.93M

Gross profit—

Free cash flow-282.61M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out82.57M

Employees479

ListedFri, Jul 20, 2018

Free float62.65M

Float %75.9%

Short interest23.67M

Days to cover6.4d

Short volume76.1%

Squeeze score100 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.76 vs −$0.73

Last surprise-4.1% miss

Setup gradeA+

Conviction92 / 100

Pattern quality—

Tech rank90.1 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance12.37

Support6.36

Days since event—

Candle confirm—

News sentiment—

Financials as of Wed, Dec 31, 2025 · quarterly.

Signal lifecycle

How this symbol has moved through the lanes across 32 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

Setting up
Jun 18
1 scan
→
Breaking out now
Jun 22
1 scan

Congress activity

Disclosed STOCK Act trades in REPL

All disclosures →

No recent disclosed trades by Congress in REPL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in REPL · 7 sells

Insider	Side	Shares	Value	Traded	Filed
Sarchi Christopher Chief Commercial Officer · Common Stock · 2026-06-01	Sell	12K	$111K	2026-06-01	2026-06-03
Xynos Konstantinos Chief Medical Officer · Common Stock · 2026-05-18	Sell	14.02K	$71K	2026-05-18	2026-05-20
Sarchi Christopher Chief Commercial Officer · Common Stock · 2026-05-18	Sell	8.63K	$44K	2026-05-18	2026-05-20
Patel Sushil Chief Executive Officer · Common Stock · 2026-05-18	Sell	37.32K	$190K	2026-05-18	2026-05-20
Schwendenman Andrew Chief Accounting Officer · Common Stock · 2026-05-18	Sell	7.89K	$40K	2026-05-18	2026-05-20
Hill Emily Luisa Chief Financial Officer · Common Stock · 2026-05-18	Sell	7.81K	$40K	2026-05-18	2026-05-20
Astley-Sparke Philip Director · Common Stock · 2026-05-18	Sell	17.66K	$90K	2026-05-18	2026-05-20

SEC filings

EDGAR filings in REPL · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.